A5078531443- Sarcoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Neuroblastoma Research and Treatments
- Cardiac tumors and thrombi
- Lung Cancer Treatments and Mutations
- Testicular diseases and treatments
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Gastrointestinal Tumor Research and Treatment
- Virus-based gene therapy research
- Bone Tumor Diagnosis and Treatments
- Peptidase Inhibition and Analysis
- Tumors and Oncological Cases
- Epigenetics and DNA Methylation
- Carbon Dioxide Capture Technologies
- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- Chemical Looping and Thermochemical Processes
- Cell Adhesion Molecules Research
- Cancer Diagnosis and Treatment
- Industrial Gas Emission Control
- Cancer Research and Treatments
- RNA Interference and Gene Delivery
- HER2/EGFR in Cancer Research
The University of Texas MD Anderson Cancer Center
2014-2024
Baylor College of Medicine
2019-2022
Children's Cancer Center
2019-2022
University of Utah
1986-1993
University of Idaho
1986
Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of NCCN Guidelines for provides recommendations diagnosis, risk classification, and treatment neuroblastoma. The information these guidelines was developed by Panel, a multidisciplinary group representatives with expertise neuroblastoma, consisting pediatric oncologists, radiologists, pathologists, surgeons, radiation oncologists from Member Institutions. evidence-based consensus contained...
Abstract Background Alveolar soft part sarcoma (ASPS) is a rare mesenchymal tumor characterized by ASPL‐TFE3 translocation. Apart from complete surgical resection, there no standard management strategy. Procedure The clinical data of 69 children and young adults less than 30 years old with ASPS diagnosed 1980–2014 were retrospectively collected four major institutions. Results Median age at diagnosis was 17 (range: 1.5–30). Forty‐four (64%) female. follow‐up 46 months 1–409). Most common...
Abstract Immunoconjugates targeting cell-surface antigens have demonstrated clinical activity to enable regulatory approval in several solid and hematologic malignancies. We hypothesize that a rigorous comprehensive surfaceome profiling approach identify osteosarcoma-specific can similarly development of effective therapeutics this disease. Herein, we describe an integrated proteomic transcriptomic proteins are highly expressed osteosarcoma but minimally on normal tissues. Using approach,...
Abstract Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with may be referred enrollment in early-phase trials. This study aimed to investigate whether biomarker-matched clinical trials leads better outcomes advanced sarcoma. Experimental Design: In this retrospective analysis, investigational treatment characteristics and longitudinal survival were analyzed biopsy-confirmed enrolled...
Abstract Introduction The impact of established prognostic factors on survival outcomes for childhood rhabdomyosarcoma (RMS) have not been well described in the adolescent and young adult (AYA) RMS patient population. Methods This is a retrospective analysis patients with newly diagnosed enrolled between 1997 2016 seven previously reported Children's Oncology Group (COG) clinical trials. Demographics, features, treatment details, outcome data were collected. Five‐year event‐free (EFS)...
Membrane protein leucine-rich repeat containing 15 (LRRC15) is known to be expressed in several solid tumors including osteosarcoma. ABBV-085, an antibody-drug conjugate against LRRC15, conjugated monomethyl auristatin E (MMAE), was studied osteosarcoma patient-derived xenografts (PDXs) by the Pediatric Preclinical Testing Consortium (PPTC). LRRC15 expression data were obtained from PPTC RNA-sequencing for PDX models. The TARGET database mined human Protein confirmed via IHC three Seven...
Abstract Background Novel therapies are needed for relapsed and refractory rhabdomyosarcoma (RRMS). Phase II clinical trials in RRMS have typically utilized radiologic response as the primary activity endpoint, an approach that poses several limitations RRMS. In this analysis, we aimed to estimate event‐free survival (EFS) endpoint could be used a benchmark future studies. Procedure We performed retrospective study of patients with enrolling on 13 single‐agent phase Children's Oncology Group...
Systemic therapy has improved rhabdomyosarcoma event-free and overall survival; however, approximately 40 % of patients will have progressive or recurrent disease which is difficult to cure remains a considerable challenge. Minimal progress been made in improving outcomes for metastatic relapsed RMS due lack effective therapeutic agents. Targeted therapies are likely be incorporated into regimens rely on conventional cytotoxic chemotherapy. A system evaluate novel combinations interest...
ABSTRACT Background Strategies to optimize management in rhabdomyosarcoma (RMS) include risk stratification assign therapy aiming minimize treatment morbidity yet improve outcomes. This analysis evaluated the relationship between complete metabolic response (CMR) as assessed by 18 F‐fluorodeoxyglucose positron emission tomography‐computed tomography (FDG‐PET) imaging and event‐free survival (EFS) intermediate‐risk (IR) high‐risk (HR) RMS patients. Methods FDG‐PET characteristics, including...
Abstract HER2 is expressed in many pediatric solid tumors and a target for innovative immune therapies including CAR-T cells antibody–drug conjugates (ADC). We evaluated the preclinical efficacy of trastuzumab deruxtecan (T-DXd, DS-8201a), humanized monoclonal HER2-targeting antibody conjugated to topoisomerase 1 inhibitor, DXd, patient- cell line–derived xenograft (PDX/CDX) models. mRNA expression was determined using RNA-seq protein via IHC across multiple tumor PDX Osteosarcoma (OS),...
Abstract Background Temsirolimus has shown in vivo activity against rhabdomyosarcoma (RMS). We aimed to determine the feasibility of incorporating temsirolimus within standard Children's Oncology Group (COG) chemotherapy backbone vincristine, actinomycin‐D, and cyclophosphamide (VAC) alternating with vincristine irinotecan (VI) children intermediate‐risk (IR) RMS. Methods The phase COG IR‐RMS trial, ARST1431 (NCT02567435), assigned 10 patients receive 15 mg/m 2 /dose (dose level 1) on days...
Thermogravimetric analysis was done for representative calcined samples of Ontario limestones and dolomites in a 5% SO 2 controlled atmosphere. The absorption vs. temperature curves showed three distinct regions. (i) A unimolecular chemisorption at room temperature. (ii) An intermediate region between 200–450 °C where due to increased rate diffusion into the interior CaO via grain boundaries. When surfaces these internal spaces were almost fully occupied decreased. Further lattice, which...
11514 Background: Ewing sarcoma (ES), a rare bone and soft tissue mainly of adolescents young adults, is characterized by chromosomal translocation resulting in fusion oncoprotein. Lysine specific demethylase 1 (LSD1) has been shown to associate with the oncoprotein promote oncogenic transcriptional activity making LSD1 an attractive target for ES treatment. Seclidemstat novel, selective, reversible oral inhibitor capable inhibiting both LSD1’s catalytic scaffolding functions. This first...